Press releases Nektar in the news Items Per Page 10 25 50 News Category All Financial General Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Oct 01, 2026 New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 Sep 30, 2026 New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis Sep 28, 2026 Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 Sep 25, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 28, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 25, 2026 Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Aug 13, 2026 Nektar Therapeutics Announces Second Quarter 2026 Financial Results Jul 28, 2026 Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets Jul 24, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 21, 2026 Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Contact IR Print Page RSS Email Alerts
Nektar in the news Items Per Page 10 25 50 News Category All Financial General Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Oct 01, 2026 New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 Sep 30, 2026 New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis Sep 28, 2026 Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 Sep 25, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 28, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 25, 2026 Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Aug 13, 2026 Nektar Therapeutics Announces Second Quarter 2026 Financial Results Jul 28, 2026 Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets Jul 24, 2026 Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 21, 2026 Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Oct 01, 2026 New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
Sep 30, 2026 New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
Sep 28, 2026 Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
Aug 25, 2026 Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Jul 28, 2026 Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
Jul 21, 2026 Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
